Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

EQ-5D studies in nervous system diseases in eight Central and East European countries: a systematic literature review

V. Prevolnik Rupel, M. Divjak, Z. Zrubka, F. Rencz, L. Gulácsi, D. Golicki, D. Mirowska-Guzel, J. Simon, V. Brodszky, P. Baji, J. Závada, G. Petrova, A. Rotar, M. Péntek,

. 2019 ; 20 (Suppl 1) : 109-117. [pub] 20190516

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články, systematický přehled

Perzistentní odkaz   https://www.medvik.cz/link/bmc20006357

BACKROUND: Guidelines for economic analyses of health care technologies require local input data for reimbursement decisions in the countries of Central and Eastern Europe (CEE). The aim of this study was to systematically review and analyse the available empirical studies using the EQ-5D instrument as a measure of the health-related quality of life (HRQoL) in patients with neurological diseases. METHODS: A systematic literature search was performed up to 1st April 2018 to identify relevant studies in eight selected CEE countries. Original articles reporting on studies of neurological diseases using the EQ-5D instrument were analysed. RESULTS: Thirty-six articles, describing the results of 38 samples of patients and a total of 13,005 patients were included in the review. Most studies were from Hungary (44.4%) and none from Romania or Slovakia. EQ-5D utility scores were reported in 33 (91.7%) articles. In multiple sclerosis (MS) being the most represented disease, the average utility scores ranged from 0.49 in Austria to 0.80 in Poland with a weighted average of 0.69. EQ VAS scores for MS ranged from 39 in Czech Republic to 72.0 in Poland, with weighted average of 59.1. MS patients, together with epilepsy and essential tremor patients, estimated their HRQoL among the highest. CONCLUSIONS: EQ-5D research activity in neurology has been increasing through the years in studied CEE countries. There are clinical areas with the significant social burden, such as a migraine or meningitis, that are completely lacking data, other areas, such as stroke or epilepsy, with very scarce data.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20006357
003      
CZ-PrNML
005      
20200526095306.0
007      
ta
008      
200511s2019 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s10198-019-01068-9 $2 doi
035    __
$a (PubMed)31098882
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Prevolnik Rupel, Valentina $u Institute for Economic Research, Kardeljeva ploščad 17, 1000, Ljubljana, Slovenia. rupelv@ier.si.
245    10
$a EQ-5D studies in nervous system diseases in eight Central and East European countries: a systematic literature review / $c V. Prevolnik Rupel, M. Divjak, Z. Zrubka, F. Rencz, L. Gulácsi, D. Golicki, D. Mirowska-Guzel, J. Simon, V. Brodszky, P. Baji, J. Závada, G. Petrova, A. Rotar, M. Péntek,
520    9_
$a BACKROUND: Guidelines for economic analyses of health care technologies require local input data for reimbursement decisions in the countries of Central and Eastern Europe (CEE). The aim of this study was to systematically review and analyse the available empirical studies using the EQ-5D instrument as a measure of the health-related quality of life (HRQoL) in patients with neurological diseases. METHODS: A systematic literature search was performed up to 1st April 2018 to identify relevant studies in eight selected CEE countries. Original articles reporting on studies of neurological diseases using the EQ-5D instrument were analysed. RESULTS: Thirty-six articles, describing the results of 38 samples of patients and a total of 13,005 patients were included in the review. Most studies were from Hungary (44.4%) and none from Romania or Slovakia. EQ-5D utility scores were reported in 33 (91.7%) articles. In multiple sclerosis (MS) being the most represented disease, the average utility scores ranged from 0.49 in Austria to 0.80 in Poland with a weighted average of 0.69. EQ VAS scores for MS ranged from 39 in Czech Republic to 72.0 in Poland, with weighted average of 59.1. MS patients, together with epilepsy and essential tremor patients, estimated their HRQoL among the highest. CONCLUSIONS: EQ-5D research activity in neurology has been increasing through the years in studied CEE countries. There are clinical areas with the significant social burden, such as a migraine or meningitis, that are completely lacking data, other areas, such as stroke or epilepsy, with very scarce data.
650    _2
$a činnosti denního života $7 D000203
650    _2
$a lidé $7 D006801
650    _2
$a duševní zdraví $7 D008603
650    _2
$a nemoci nervového systému $x epidemiologie $x psychologie $7 D009422
650    _2
$a bolest $x epidemiologie $7 D010146
650    _2
$a tělesná a funkční výkonnost $7 D000076604
650    _2
$a kvalita života $x psychologie $7 D011788
650    _2
$a péče o sebe $7 D012648
650    _2
$a stupeň závažnosti nemoci $7 D012720
651    _2
$a Evropa $x epidemiologie $7 D005060
651    _2
$a východní Evropa $x epidemiologie $7 D005061
655    _2
$a časopisecké články $7 D016428
655    _2
$a systematický přehled $7 D000078182
700    1_
$a Divjak, Marko $u DOBA Business School, Prešernova ulica 1, 2000, Maribor, Slovenia.
700    1_
$a Zrubka, Zsombor $u Department of Health Economics, Corvinus University of Budapest, Fővám tér 8., H-1093, Budapest, Hungary. Doctoral School of Management, Corvinus University of Budapest, Fővám tér 8., Budapest, 1093, Hungary.
700    1_
$a Rencz, Fanni $u Department of Health Economics, Corvinus University of Budapest, Fővám tér 8., H-1093, Budapest, Hungary. Premium Postdoctoral Research Programme, Hungarian Academy of Sciences, Nádor u. 7, Budapest, 1051, Hungary.
700    1_
$a Gulácsi, László $u Department of Health Economics, Corvinus University of Budapest, Fővám tér 8., H-1093, Budapest, Hungary.
700    1_
$a Golicki, Dominik $u Department of Experimental and Clinical Pharmacology, Center for Preclinical Research and Technology, Medical University of Warsaw, Poland, ul. Banacha 1b, 02-097, Warsaw, Poland.
700    1_
$a Mirowska-Guzel, Dagmara $u Department of Experimental and Clinical Pharmacology, Center for Preclinical Research and Technology, Medical University of Warsaw, Poland, ul. Banacha 1b, 02-097, Warsaw, Poland.
700    1_
$a Simon, Judit $u Department of Health Economics, Centre for Public Health, Medical University of Vienna, Kinderspitalgasse 15/1, Vienna, 1090, Austria.
700    1_
$a Brodszky, Valentin $u Department of Health Economics, Corvinus University of Budapest, Fővám tér 8., H-1093, Budapest, Hungary.
700    1_
$a Baji, Petra $u Department of Health Economics, Corvinus University of Budapest, Fővám tér 8., H-1093, Budapest, Hungary.
700    1_
$a Závada, Jakub $u Institute of Rheumatology, Na Slupi 4, 128 00, Prague, Czech Republic.
700    1_
$a Petrova, Guenka $u Department of Social Pharmacy and Pharmacoeconomics, Faculty of Pharmacy, Medical University, Sofia, Bulgaria.
700    1_
$a Rotar, Alexandru $u Department of Social Medicine, University of Amsterdam, Meibergdreef 9, 22660, 1100 DD, Amsterdam, The Netherlands.
700    1_
$a Péntek, Márta $u Department of Health Economics, Corvinus University of Budapest, Fővám tér 8., H-1093, Budapest, Hungary.
773    0_
$w MED00007432 $t The European journal of health economics : HEPAC : health economics in prevention and care $x 1618-7601 $g Roč. 20, Suppl 1 (2019), s. 109-117
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31098882 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20200526095303 $b ABA008
999    __
$a ok $b bmc $g 1525215 $s 1096413
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 20 $c Suppl 1 $d 109-117 $e 20190516 $i 1618-7601 $m The European journal of health economics $n Eur J Health Econ $x MED00007432
LZP    __
$a Pubmed-20200511

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace